Search clinical trials for: immune Checkpoint Inhibitors

Total 108457 results

West China Hospital

Not yet recruiting

Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

NSCLC Associated With Leptomeningeal Metastases
Chang Gung Memorial Hospital

Recruiting

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma (ProtonAB)

Hepatocellular Carcinoma Non-resectable

Taiwan
Memorial Sloan Kettering Cancer Center
Exelixis

Recruiting

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Metastatic Renal Cell Carcinoma | Brain Metastases

United States
Amgen

Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Taiwan, Australia, United States, Japan, Canada, Korea, Republic of, Poland
Maria Sklodowska-Curie National Research Institute...
Immutep S.A.S.

Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO)

Immunotherapy | Sarcoma,Soft Tissue | Radiation Therapy | Neoadjuvant

Poland
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
First Affiliated Hospital of Guangxi Medical University

Recruiting

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Colonic Neoplasms | Neoadjuvant Therapy | Immune Checkpoint Inhibitors

China
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Genentech, Inc.

Recruiting

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Esophageal Cancer | Gastric Adenocarcinoma | HER2 Gene Mutation

United States
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Spain, Brazil, China, Colombia, Italy, Saudi Arabia, Taiwan, Thailand, United States, Korea, Republic of, Argentina, France, Mexico, Turkey
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States, China, Taiwan, Belgium, Australia, Japan, United Kingdom, Spain, France, Germany, Austria, Korea, Republic of, Hungary, Switzerland, Mexico, Norway, Italy, Turkey, Greece, Portugal, Netherlands, India, Romania, Canada, De... and more
Erasmus Medical Center

Recruiting

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE)

Melanoma

Netherlands
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
Mohammed Milhem

Recruiting

Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)

Undifferentiated Pleomorphic Sarcoma

United States
Biocad

Recruiting

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Advanced Melanoma

Russian Federation, Belarus
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

China, United States, Italy, Spain, United Kingdom, Korea, Republic of, Canada, Germany, Poland, Belgium, Japan, Vietnam, Bulgaria, France, Brazil, India, Malaysia, Taiwan, Thailand, Hungary, Australia, Austria, Turkey, Hong Kong, Switz... and more
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

Spain, United States, Australia, Austria, Poland, France, Germany, Italy, Switzerland
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric Cancer | GastroEsophageal Cancer

United States
Vanderbilt-Ingram Cancer Center
Genentech, Inc.

Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT)

Stage IV Lung Cancer | Extensive Stage Lung Small Cell Carcinoma

United States
AbbVie

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)

Hepatocellular Carcinoma

United States, Taiwan, Spain, France, Italy
Jules Bordet Institute

Recruiting

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors (LIFE)

Non Small Cell Lung Cancer

Belgium
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC

Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Wuhan Union Hospital, China

Recruiting

Fruquintinib in the Cross-line Treatment of Refractory mCRC

Metastatic Colorectal Cancer | Fruquintinib

China
Assiut University

Recruiting

Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI (NSCLC)

Diabetes Mellitus | Non Small Cell Lung Cancer Metastatic

Egypt
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
Beijing Tongren Hospital

Not yet recruiting

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma

United States
Base Therapeutics (Shanghai) Co., Ltd.
The General Hospital of Eastern Theater Command

Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

NSCLC

China
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, Poland, United States, Canada, Japan, United Kingdom, Spain, China, France, Taiwan, Norway, Brazil, Germany, Switzerland, South Africa, Turkey, Netherlands
Genentech, Inc.

Recruiting

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros)

Hepatocellular Carcinoma

United States, Puerto Rico
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
National Cancer Institute (NCI)

Recruiting

Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Not yet recruiting

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Not yet recruiting

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) (PANDORA)

Merkel Cell Carcinoma

Italy
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Tianjin Medical University Cancer... and other collaborators

Recruiting

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Esophageal Neoplasm Metastatic | Esophageal Cancer Stage IVb

China
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
West German Study Group
Merck Sharp & Dohme LLC; Gilead Sciences

Not yet recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (ADAPT-TN-III)

Triple Negative Breast Cancer
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States, Belgium, Bulgaria, France, Italy, Korea, Republic of, Romania, Slovakia
Boehringer Ingelheim

Recruiting

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREONᵀᴹ-8)

Small Cell Lung Carcinoma (SCLC)

Spain, Belgium, Japan, France, Poland, Germany
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

Poland, United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Canada, Lithuania, Norway, Italy, Czechia, Estonia, Portugal, Denmark, Latvia
UNICANCER
SOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...

Not yet recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC (ETNA)

Triple-negative Breast Cancer
Chuangzhen Chen

Recruiting

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors (ILDRV1)

Radiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to Immunotherapy

China
Duke University

Recruiting

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial (MOAB)

Recurrent Glioblastoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Adrenocortical Carcinoma | ACC | Metastatic Adrenocortical Carcinoma

United States

Search clinical trials for: immune Checkpoint Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations